Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$10.51 -3.0%	$10.34	$3.85 ▼ $12.43	$1.60B	1.83	1.64 million shs	819,860 shs
MREO Mereo BioPharma Group	$1.80 +2.6%	$2.48	$1.57 ▼ $5.02	$285.41M	0.46	1.34 million shs	2.90 million shs
SRPT Sarepta Therapeutics	$22.02 +19.8%	$29.15	$16.88 ▼ $150.48	$2.17B	0.45	2.37 million shs	15.72 million shs
TARS Tarsus Pharmaceuticals	$41.51 -0.1%	$42.00	$20.08 ▼ $57.28	$1.74B	0.8	682,773 shs	165,121 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	-2.08%	-9.22%	+5.25%	+47.75%	+143.37%
MREO Mereo BioPharma Group	+2.34%	-40.48%	-36.59%	-23.91%	-57.21%
SRPT Sarepta Therapeutics	+0.93%	-5.11%	-12.23%	-65.83%	-87.66%
TARS Tarsus Pharmaceuticals	+2.39%	+0.63%	+0.63%	-15.63%	+45.94%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	2.7145 of 5 stars	1.4	1.0	4.2	2.5	2.5	0.6
MREO Mereo BioPharma Group	1.5828 of 5 stars	3.6	1.0	0.0	1.5	1.7	0.0
SRPT Sarepta Therapeutics	4.7411 of 5 stars	4.2	2.0	4.2	2.9	1.7	1.9
TARS Tarsus Pharmaceuticals	1.7787 of 5 stars	3.5	0.0	0.0	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.86	Moderate Buy	$10.57	0.58% Upside
MREO Mereo BioPharma Group	3.20	Buy	$7.20	301.11% Upside
SRPT Sarepta Therapeutics	2.44	Hold	$57.00	158.87% Upside
TARS Tarsus Pharmaceuticals	3.00	Buy	$66.67	60.61% Upside

Current Analyst Ratings Breakdown

Latest MREO, ADPT, SRPT, and TARS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $65.00
7/17/2025	SRPT Sarepta Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$29.00 ➝ $32.00
7/17/2025	SRPT Sarepta Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$25.00 ➝ $23.00
7/17/2025	SRPT Sarepta Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
7/17/2025	SRPT Sarepta Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$30.00 ➝ $35.00
7/10/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$7.00 ➝ $5.00
7/10/2025	SRPT Sarepta Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$30.00 ➝ $28.00
6/25/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Sell
6/20/2025	SRPT Sarepta Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$123.00 ➝ $45.00
6/20/2025	SRPT Sarepta Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
6/18/2025	ADPT Adaptive Biotechnologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$178.96M	8.92	N/A	N/A	$1.37 per share	7.67
MREO Mereo BioPharma Group	$10M	28.54	N/A	N/A	$0.39 per share	4.60
SRPT Sarepta Therapeutics	$1.90B	1.14	$2.94 per share	7.48	$15.99 per share	1.38
TARS Tarsus Pharmaceuticals	$233.67M	7.46	N/A	N/A	$5.87 per share	7.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.96	N/A	N/A	N/A	-74.84%	-62.79%	-24.55%	8/5/2025 (Estimated)
MREO Mereo BioPharma Group	-$43.25M	-$0.07	N/A	N/A	N/A	N/A	-69.33%	-57.27%	8/12/2025 (Estimated)
SRPT Sarepta Therapeutics	$235.24M	-$2.69	N/A	2.01	N/A	-11.12%	-14.88%	-5.12%	8/6/2025 (Estimated)
TARS Tarsus Pharmaceuticals	-$115.55M	-$2.73	N/A	N/A	N/A	-44.91%	-39.72%	-25.74%	8/6/2025 (Estimated)

Latest MREO, ADPT, SRPT, and TARS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	TARS Tarsus Pharmaceuticals	-$0.41	N/A	N/A	N/A	$95.81 million	N/A
8/12/2025	Q2 2025	MREO Mereo BioPharma Group	-$0.01	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	SRPT Sarepta Therapeutics	$0.89	N/A	N/A	N/A	$530.66 million	N/A
8/5/2025	Q2 2025	ADPT Adaptive Biotechnologies	-$0.24	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	MREO Mereo BioPharma Group	-$0.01	-$0.02	-$0.01	-$0.02	$72.50 million	N/A
5/6/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	-$3.42	-$5.62	-$4.60	$685.75 million	$744.86 million
5/1/2025	Q1 2025	ADPT Adaptive Biotechnologies	-$0.28	-$0.20	+$0.08	-$0.20	$42.13 million	$52.44 million
5/1/2025	Q1 2025	TARS Tarsus Pharmaceuticals	-$0.69	-$0.64	+$0.05	-$0.64	$72.50 million	$78.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.92	2.82
MREO Mereo BioPharma Group	N/A	8.92	8.92
SRPT Sarepta Therapeutics	1.00	4.02	2.46
TARS Tarsus Pharmaceuticals	0.21	5.57	5.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
MREO Mereo BioPharma Group	62.83%
SRPT Sarepta Therapeutics	86.68%
TARS Tarsus Pharmaceuticals	90.01%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
MREO Mereo BioPharma Group	5.50%
SRPT Sarepta Therapeutics	7.70%
TARS Tarsus Pharmaceuticals	8.97%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	151.92 million	142.19 million	Optionable
MREO Mereo BioPharma Group	40	159.00 million	150.26 million	Optionable
SRPT Sarepta Therapeutics	1,372	98.28 million	90.71 million	Optionable
TARS Tarsus Pharmaceuticals	50	42.01 million	38.25 million	Optionable

MREO, ADPT, SRPT, and TARS Headlines

Recent News About These Companies

Tarsus Pharmaceuticals: Making Big Strides

4 hours ago | seekingalpha.com

William Blair Issues Pessimistic Estimate for TARS Earnings

July 16 at 6:02 AM | marketbeat.com

William Blair Has Bearish Estimate for TARS FY2026 Earnings

July 16 at 2:01 AM | americanbankingnews.com

What is William Blair's Estimate for TARS FY2026 Earnings?

July 15 at 8:23 AM | marketbeat.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $66.67 Consensus PT from Analysts

July 15 at 2:17 AM | americanbankingnews.com

Tarsus Pharmaceuticals Stock Price, Quotes and Forecasts

July 13, 2025 | benzinga.com

Hot Tick Summer Is Here. Here’s What You Need to Know and How to Stay Safe

July 12, 2025 | gizmodo.comG

Grant GrossMendelsohn LLC Sells 26,143 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

July 12, 2025 | marketbeat.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Buy" by Analysts

July 12, 2025 | marketbeat.com

Allspring Global Investments Holdings LLC Sells 12,401 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

July 5, 2025 | marketbeat.com

Tarsus Pharmaceuticals Inc Ordinary Shares - Morningstar

July 2, 2025 | morningstar.comM

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Lisanti Capital Growth LLC

June 29, 2025 | marketbeat.com

Tarsus Pharmaceuticals Becomes Oversold (TARS)

June 19, 2025 | nasdaq.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by GAMMA Investing LLC

June 19, 2025 | marketbeat.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Buy" by Brokerages

June 17, 2025 | marketbeat.com

Tarsus Pharmaceuticals CCO sells $765,800 in stock

June 13, 2025 | investing.com

Tarsus Pharmaceuticals CCO sells $765,800 in stock

June 13, 2025 | investing.com

Stocks Showing Improving Market Leadership: Tarsus Pharmaceuticals Earns 87 RS Rating

June 6, 2025 | msn.com

Tarsus Pharmaceuticals assumed with an Outperform at Oppenheimer

June 2, 2025 | msn.com

Tarsus to Participate in Upcoming Investor Conferences

May 29, 2025 | globenewswire.com

Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

May 27, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MREO, ADPT, SRPT, and TARS Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$10.51 -0.32 (-2.95%)

As of 02:59 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Mereo BioPharma Group NASDAQ:MREO

$1.80 +0.05 (+2.57%)

As of 02:59 PM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Sarepta Therapeutics NASDAQ:SRPT

$22.02 +3.64 (+19.80%)

As of 02:59 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Tarsus Pharmaceuticals NASDAQ:TARS

$41.51 -0.04 (-0.10%)

As of 02:59 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time